Synairgen PLC (AIM:SNG, OTC:SYGGF) has welcomed Dr. Marcin Mankowski, a veteran pharmaceutical physician and drug developer, as its chief medical officer with immediate effect.
Synairgen plc (AIM:SNG) Synairgen presents at ATS 2022
Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022
Synairgen plc (SNG.L) SNG001 progresses to Phase 3 of ACTIV-2 trial
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored
Synairgen plc (SNG.L) Home Cohort data of SG016 Phase II trial
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
Synairgen plc (SNG.L) Inclusion in US ACTIV-2 trial
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
Synairgen plc (SNG.L) COVID-19 Clinical Programme Update
– SNG001 given Fast Track designation and IND cleared by the US FDA – Phase III trial design adapted which will expedite results – Phase III trial to commence dosing
Synairgen plc (SNG.L) Lancet Respiratory Medicine publishes Phase 2 data
Data from SG016 Phase II Clinical Trial published in Lancet Respiratory Medicine
Synairgen plc (SNG.L) positive results from trial of SNG001 in hospitalised COVID-19 patients
Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo Patients who received SNG001 were more than twice as likely to recover from COVID-19